Tsutomu Ueda

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3K citations · Full text

Neoadjuvant Therapy, Chemotherapy Versus Cetuximab, Medicine +7

Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

Jean‐Pascal Machiels, Yungan Tao, Lisa Licitra et al. · The Lancet Oncology · 2024 · 174 citations · Full text

Concurrent Chemoradiotherapy, Neoadjuvant Therapy, Squamous Cell Carcinoma +6

Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer

Ravindra Uppaluri, Robert I. Haddad, Yungan Tao et al. · New England Journal of Medicine · 2025 · 153 citations

Flotillin-2 deficiency leads to reduced lung metastases in a mouse breast cancer model

Thorsten Berger, Tsutomu Ueda, Enrico Arpaia et al. · Oncogene · 2012 · 54 citations · Full text

Lung Metastases, Flotillin-2 Deficiency, Breast Oncology +9

Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real-world clinical practice: a multicenter retrospective clinical study

Nobuhiro Hanai, Yasushi Shimizu, Shin Kariya et al. · International Journal of Clinical Oncology · 2020 · 54 citations · Full text